Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 101-110 of 411 for multiple

Edit search filters
  1. Study Comparing Daratumumab, Lenalidomide, And Dexamethasone With Lenalidomide And Dexamethasone In Participants With Previously Untreated Multiple Myeloma

    Jacksonville, FL, Rochester, MN

  2. A Study Of WVT078 In Patients With Multiple Myeloma

    Rochester, MN

  3. A Study To Examine The Effects Of Novel Therapy Linvoseltamab In Combination With Other Cancer Treatments For Adult Participants With Multiple Myeloma That Is Resistant To Current Standard Of Care Treatments

    Rochester, MN

  4. A Study To Determine The Effect Of Distance Reiki On Patient Reported Quality Of Life (PRQoL) And Immunity Among Multiple Myeloma Patients

    Rochester, MN

  5. A Study Of JNJ-68284528, A Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) In Participants With Multiple Myeloma

    Rochester, MN

  6. A Study To Evaluate Pembrolizumab, Ixazomib Citrate, And Dexamethasone To Treat Participants With Relapsed Multiple Myeloma

    Rochester, MN

  7. A Study To Evaluate Daratumumab/rHuPh20 +/- Lenalidomide As Post-ASCT Maintenance For Multiple Myeloma With Minimal Residual Disease (MRD) To Direct Therapy Duration

    Scottsdale/Phoenix, AZ, Eau Claire, WI, Rochester, MN

  8. A Study Of An MMSET Inhibitor In Patients With Relapsed And Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  9. A Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of HPN217 In Patients With Relaped/Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ

  10. A Study Of JNJ-68284528, A Therapy Directed Against B-Cell Maturation Antigen (BCMA) In Participants With Relapsed Or Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Rochester, MN

.

Mayo Clinic Footer